SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing

Based on Highly-Purified Isomers of Tannic Acid and Acting as a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir Has Shown Significant Anti-Viral Properties  with Minimal Observed Side Effects NEW TAIPEI CITY, Taiwan and TORRANCE, Calif., Nov. 20, 2021 /PRNewswire/ -- SyneuRx™ International, (Ta...